Clinical Trial Update: Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating tipranavir/ritonavir, ribavirin, and pegylated interferon in subjects with mild hepatic impairment (Hepatitis C) and in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alcoholic Liver Disease
• Hepatitis B
• Hepatitis C
• Hepatitis D
• Liver Cirrhosis

Drugs mentioned

• Pegylated interferon (pegylated interferon alfa)
• Ribavirin (ribavirin)
• tipranavir/ritonavir (tipranavir/ritonavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Hepatic Insufficiency | Phase 1 | Status: COMPLETED